Table 5

Hematological parameters values at baseline and following 15 weeks of double-blind treatment

PS-DHA

Placebo


Variable

Baseline (mean ± SD)

15 weeks

(mean ± SD)

P value1 (within group)

Baseline (mean ± SD)

15 weeks

(mean ± SD)

P value1 (within group)

P value2 (between groups)


White blood cell count (×103/cmm)

6.8 ± 1.8

6.5 ± 1.6

0.083

7.1 ± 2.0

6.7 ± 1.9

0.011*

0.434


Male

6.8 ± 1.7

6.4 ± 1.5

0.020*

7.3 ± 2.3

7.1 ± 2.2

0.298

0.467


Female

6.7 ± 1.9

6.7 ± 1.6

0.829

6.9 ± 1.4

6.3 ± 1.3

0.009*

0.066


Red blood cell count (×106/cmm)

4.6 ± 0.5

4.6 ± 0.5

0.441

4.6 ± 0.4

4.6 ± 0.4

0.332

0.765


Male

4.7 ± 0.5

4.7 ± 0.5

0.544

4.6 ± 0.4

4.6 ± 0.4

0.491

0.925


Female

4.5 ± 0.4

4.4 ± 0.4

0.622

4.5 ± 0.4

4.5 ± 0.4

0.488

0.760


Hematocrit (%)

41.2 ± 4.2

40.7 ± 4.3

0.113

41.6 ± 3.6

40.9 ± 3.6

0.045*

0.504


Male

42.5 ± 4.3

42.1 ± 4.4

0.229

42.6 ± 3.6

42.0 ± 3.4

0.100

0.763


Female

39.8 ± 3.7

39.4 ± 3.8

0.309

40.5 ± 3.2

39.6 ± 3.5

0.193

0.548


Hemoglobin (g/dL)

13.7 ± 1.5

13.7 ± 1.5

0.434

13.7 ± 1.2

13.6 ± 1.2

0.213

0.669


Male

14.3 ± 1.4

14.3 ± 1.3

0.706

14.1 ± 1.2

13.9 ± 1.2

0.181

0.623


Female

13.1 ± 1.4

13.0 ± 1.4

0.481

13.3 ± 1.1

13.2 ± 1.1

0.494

0.856


Platelet count (×103/cmm)

221.5 ± 62.7

226.8 ± 60.5

0.374

226.9 ± 73.7

230.8 ± 68.8

0.347

0.839


Male

200.1 ± 44.5

204.0 ± 44.3

0.479

202.8 ± 58.3

210.0 ± 61.1

0.128

0.648


Female

243.5 ± 71.3

250.2 ± 66.4

0.536

255.4 ± 80.6

255.3 ± 70.4

0.980

0.592


Netrophils (%)

62.8 ± 6.5

62.4 ± 6.4

0.514

63.8 ± 8.7

62.9 ± 8.6

0.207

0.543


Male

65.1 ± 6.0

64.4 ± 5.7

0.390

64.8 ± 9.0

64.8 ± 9.2

0.968

0.569


Female

60.4 ± 6.2

60.5 ± 6.7

0.969

62.6 ± 8.4

60.7 ± 7.5

0.097

0.147


Netrophils Absolute (×109/L)

4.3 ± 1.3

4.1 ± 1.0

0.080

4.5 ± 1.4

4.2 ± 1.4

0.037*

0.579


Male

4.5 ± 1.3

4.1 ± 1.1

0.027*

4.7 ± 1.5

4.6 ± 1.7

0.675

0.265


Female

4.1 ± 1.2

4.0 ± 1.0

0.814

4.4 ± 1.2

3.8 ± 1.0

0.010*

0.046*


Lymphocytes (%)

26.0 ± 6.1

26.1 ± 5.8

0.887

25.8 ± 8.7

26.4 ± 8.1

0.324

0.478


Male

23.8 ± 5.6

24.4 ± 5.1

0.453

24.5 ± 8.8

24.4 ± 8.7

0.893

0.529


Female

28.2 ± 5.8

27.8 ± 6.0

0.447

27.3 ± 8.4

28.8 ± 6.9

0.171

0.116


Lymphocytes Absolute (×109/L)

1.8 ± 0.6

1.7 ± 0.5

0.167

1.9 ± 1.1

1.8 ± 0.8

0.051

0.449


Male

1.6 ± 0.5

1.6 ± 0.4

0.234

1.9 ± 1.4

1.7 ± 1.0

0.115

0.468


Female

1.9 ± 0.6

1.8 ± 0.6

0.458

1.8 ± 0.6

1.8 ± 0.5

0.238

0.819


Monocytes (%)

5.8 ± 1.4

6.0 ± 1.5

0.119

5.6 ± 1.0

5.9 ± 1.4

0.093

0.918


Male

5.9 ± 1.5

6.1 ± 1.4

0.343

5.7 ± 0.9

5.9 ± 1.3

0.299

0.976


Female

5.6 ± 1.4

5.9 ± 1.6

0.220

5.5 ± 1.1

5.8 ± 1.5

0.193

0.895


Monocytes Absolute (×109/L)

0.4 ± 0.1

0.4 ± 0.1

0.731

0.4 ± 0.1

0.4 ± 0.1

0.565

0.516


Male

0.4 ± 0.1

0.4 ± 0.1

0.497

0.4 ± 0.1

0.4 ± 0.1

0.890

0.556


Female

0.4 ± 0.1

0.4 ± 0.1

0.284

0.4 ± 0.1

0.4 ± 0.1

0.359

0.159


Eosinophils (%)

3.0 ± 2.5

3.1 ± 3.3

0.365

2.5 ± 1.6

2.5 ± 1.5

0.844

0.540


Male

2.7 ± 1.5

2.8 ± 2.0

0.535

2.8 ± 1.8

2.7 ± 1.7

0.832

0.533


Female

3.3 ± 3.3

3.5 ± 4.2

0.513

2.2 ± 1.4

2.3 ± 1.2

0.660

0.796


Eosinophils Absolute (×109/L)

0.2 ± 0.3

0.2 ± 0.3

0.853

0.2 ± 0.1

0.2 ± 0.1

0.227

0.400


Male

0.2 ± 0.2

0.2 ± 0.2

0.421

0.2 ± 0.1

0.2 ± 0.1

0.280

0.943


Female

0.2 ± 0.4

0.3 ± 0.5

0.382

0.1 ± 0.1

0.1 ± 0.1

0.513

0.284


Basophils (%)

0.7 ± 0.3

0.6 ± 0.3

0.041*

0.7 ± 0.3

0.6 ± 0.3

0.101

0.684


Male

0.7 ± 0.3

0.6 ± 0.3

0.207

0.6 ± 0.3

0.6 ± 0.3

0.099

0.882


Female

0.8 ± 0.2

0.6 ± 0.3

0.113

0.7 ± 0.4

0.7 ± 0.3

0.515

0.482


Basophils Absolute (×109/L)

0.1 ± 0.0

0.0 ± 0.0

0.006*

0.1 ± 0.0

0.0 ± 0.0

0.019*

0.854


Male

0.1 ± 0.0

0.0 ± 0.0

0.035*

0.1 ± 0.0

0.0 ± 0.0

0.058

0.928


Female

0.1 ± 0.0

0.0 ± 0.0

0.077

0.1 ± 0.0

0.0 ± 0.0

0.174

0.701


Large Unstained Cells (%)

1.7 ± 0.6

1.7 ± 0.5

1.000

1.6 ± 0.6

1.7 ± 0.6

0.162

0.306


Male

1.8 ± 0.6

1.8 ± 0.5

0.616

1.6 ± 0.6

1.6 ± 0.6

0.623

0.483


Female

1.7 ± 0.7

1.7. ± 0.6

0.701

1.7 ± 0.5

1.9 ± 0.6

0.139

0.434


Large Unstained Cells Absolute (×109/L)

0.1 ± 0.0

0.1 ± 0.0

0.652

0.1 ± 0.1

0.1 ± 0.1

0.571

0.948


Male

0.1 ± 0.0

0.1 ± 0.0

0.243

0.1 ± 0.1

0.1 ± 0.1

0.568

0.753


Female

0.1 ± 0.1

0.1 ± 0.0

0.784

0.1 ± 0.0

0.1 ± 0.0

0.847

0.742


MCV 3)

90.1 ± 4.1

89.6 ± 4.4

0.133

91.0 ± 4.3

90.1 ± 4.3

0.049*

0.506


Male

90.7 ± 4.4

90.2 ± 4.4

0.204

92.2 ± 4.3

91.4 ± 4.6

0.211

0.780


Female

89.5 ± 3.9

89.1 ± 4.31

0.397

89.6 ± 3.9

88.7 ± 3.6

0.124

0.503


MCH (pg)

30.1 ± 2.1

30.1 ± 1.9

0.850

30.0 ± 1.5

30.0 ± 1.4

0.940

0.861


Male

30.6 ± 2.2

30.7 ± 2.0

0.651

30.4 ± 1.6

30.4 ± 1.5

0.842

0.658


Female

29.5 ± 1.8

29.5 ± 1.8

0.801

29.5 ± 1.1

29.5 ± 1.1

0.910

0.810


MCHC (%)

33.4 ± 1.6

33.6 ± 1.4

0.108

33.0 ± 1.2

33.3 ± 0.9

0.041*

0.673


Male

33.8 ± 1.9

34.1 ± 1.7

0.116

33.0 ± 1.2

33.2 ± 1.1

0.267

0.794


Female

32.9 ± 1.1

33.1 ± 0.9

0.533

32.9 ± 1.1

33.3 ± 0.7

0.061

0.335


1 Based on two-sided t test for dependent samples. 2 Based on two-sided t test for independent samples

* Statistical significance was not maintained following Bonferonni correction

In the treatment arm, 33 males and 32 females had hematological blood measurements at baseline and endpoint.

In the placebo arm, 33 males and 28 females had hematological blood measurements at baseline and endpoint.

Vakhapova et al. BMC Neurology 2011 11:79   doi:10.1186/1471-2377-11-79

Open Data